Previous 10 | Next 10 |
ANN ARBOR, Mich., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the launch of “Break the Cycle with NEXLETOL”, a national direct-to-consumer (DTC) campaign aimed at broadening awareness of NEXLETOL® (bempedoic acid) Tablets and the never-endin...
ANN ARBOR, Mich., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of September. A live audio webcast of the Morgan Stanley 18 th Annual Global Healthcare...
ANN ARBOR, Mich., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will present a pooled analysis from four Phase 3 clinical trials of NEXLETOL ® (bempedoic acid) tablets as well as long-term safety and efficacy data from the CLEAR Harmony open-label ex...
Social distancing measures aimed at controlling the coronavirus pandemic have slowed down a lot of government agencies, but they haven't prevented regulators from reviewing new drug applications at a rapid pace. The FDA has already approved 35 novel new drugs this year, and keeping up with all o...
A quarterly report containing some below consensus sales for a new combination treatment from lipid-management company Esperion Therapeutics (NASDAQ: ESPR ) has ended up in at least one downgrade (to Neutral, from Credit Suisse) - but data pointing to a July prescription recovery points ...
Image source: The Motley Fool. Esperion Therapeutics Inc (NASDAQ: ESPR) Q2 2020 Earnings Call Aug 10, 2020 , 4:30 p.m. ET Operator Continue reading
Esperion Therapeutics, Inc. (ESPR) Q2 2020 Earnings Conference Call August 10, 2020 04:30 PM ET Company Participants Ben Church - Corporate Communications Tim Mayleben - President & Chief Executive Officer Mark Glickman - Chief Commercial Officer Rick Bartram - Chief Financ...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Esperion Therapeutics (NASDAQ: ESPR ) : Q2 GAAP EPS of $4.32 beats by $2.09 . More news on: Esperion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue – – Strong Capital Position with over $300 Million in Cash – – Extraordinary High-Quality Managed Care Coverage with Over 80% Com...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...